Suzanne L. Topalian

Suzanne Topalian is a pioneer in immune checkpoint therapy who conducted seminal clinical trials establishing the efficacy of anti-PD-1 antibodies across multiple cancer types. Her work was instrumental in the clinical development of nivolumab and demonstrated that PD-1 blockade could achieve durable responses in previously untreatable cancers. Topalian continues to advance understanding of immunotherapy biomarkers and resistance mechanisms.

Suzanne Topalian是免疫检查点治疗的先驱，进行了在多种癌症类型中建立抗PD-1抗体疗效的开创性临床试验。她的工作对nivolumab的临床开发起到了关键作用，并证明PD-1阻断可以在以前无法治疗的癌症中实现持久反应。Topalian继续推进对免疫治疗生物标志物和耐药机制的理解。